Title:
RECOMBINANT ONCOLYTIC VIRUS AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/012278
Kind Code:
A1
Abstract:
Provided are a recombinant oncolytic virus and the use thereof. The recombinant oncolytic virus comprises an M protein and an antigen encoded by an exogenous gene. Compared with the amino acid sequence represented by SEQ ID NO 1, the M protein comprises the following site mutations: the methionine at the 51st site being mutated into arginine (M51R); the valine at the 221st site being mutated into phenylalanine (V221F); and the serine at the 226th site being mutated into arginine (S226R). The provided recombinant oncolytic virus has good infection capability and in-vitro killing capability on abnormally proliferative (tumor) LLC cells and is not liable to be eliminated in LLC cells, and has greatly attenuated infection capability on normal cells.
Inventors:
ZHOU GUOQING (CN)
ZHANG FAN (CN)
MA LIANG (CN)
TIAN TING (CN)
ZHANG FAN (CN)
MA LIANG (CN)
TIAN TING (CN)
Application Number:
PCT/CN2023/105020
Publication Date:
January 18, 2024
Filing Date:
June 30, 2023
Export Citation:
Assignee:
JOINT BIOSCIENCES SH LTD (CN)
International Classes:
C12N7/01; A61K35/766; A61P35/00; C07K7/04; C07K14/145
Domestic Patent References:
| WO2022057904A1 | 2022-03-24 |
Foreign References:
| CN111286493A | 2020-06-16 | |||
| CN114540316A | 2022-05-27 | |||
| CN111467489A | 2020-07-31 | |||
| CN110876759A | 2020-03-13 | |||
| CN110305198A | 2019-10-08 | |||
| US20210171583A1 | 2021-06-10 | |||
| US20140088177A1 | 2014-03-27 |
Attorney, Agent or Firm:
BEIJING WEIZHENG PATENT AGENCY CO., LTD. (CN)
Download PDF:
Previous Patent: RECOMBINANT ONCOLYTIC VIRUS AND USE THEREOF
Next Patent: INFORMATION TRANSMISSION METHOD AND APPARATUS, AND DEVICE
Next Patent: INFORMATION TRANSMISSION METHOD AND APPARATUS, AND DEVICE